<- Go Home
Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren’s disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.
Market Cap
$45.1M
Volume
270.6K
Cash and Equivalents
$91.6M
EBITDA
-$49.1M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$9.2M
Profit Margin
100.00%
52 Week High
$1.60
52 Week Low
$0.67
Dividend
N/A
Price / Book Value
0.57
Price / Earnings
-0.69
Price / Tangible Book Value
0.57
Enterprise Value
-$30.5M
Enterprise Value / EBITDA
0.98
Operating Income
-$50.6M
Return on Equity
59.49%
Return on Assets
-21.73
Cash and Short Term Investments
$99.7M
Debt
$24.1M
Equity
$79.8M
Revenue
$9.2M
Unlevered FCF
-$30.7M
Sector
Biotechnology
Category
N/A